These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19576722)

  • 1. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
    Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; Giovannini M; Delpero JR
    Eur J Surg Oncol; 2009 Dec; 35(12):1306-11. PubMed ID: 19576722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
    Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
    Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
    Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; de Chaisemartin C; Giovannini M; Delpero JR
    Oncology; 2009; 76(6):413-9. PubMed ID: 19407474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
    Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
    J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
    Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
    Arvold ND; Ryan DP; Niemierko A; Blaszkowsky LS; Kwak EL; Wo JY; Allen JN; Clark JW; Wadlow RC; Zhu AX; Fernandez-Del Castillo C; Hong TS
    Cancer; 2012 Jun; 118(12):3026-35. PubMed ID: 22020923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
    Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
    Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
    Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
    J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
    Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
    Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Nukui Y; Picozzi VJ; Traverso LW
    Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.